Agios Pharmaceuticals (AGIO)

$40.50 +0.57 (1.43%)
Market Cap 2.35B
Revenue (ttm) 36.50M
Net Income (ttm) 673.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1,845.84%
Debt to Equity Ratio 0.00
Volume 525,400
Avg Vol 832,154
Day's Range N/A - N/A
Shares Out 58.10M
Stochastic %K 82%
Beta 0.83
Analysts Strong Sell
Price Target $49.28

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatr...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 649 8600
Address:
88 Sidney Street, Cambridge, United States
SweepCastApp
SweepCastApp Oct. 4 at 12:30 AM
$AGIO: Unusual Options Activity Alerted CALL flow observed 50x contracts at Strike price of $35 Exp on 10/17/2025 with Premium of $31K and showing NEUTRAL Sentiment
0 · Reply
wrengler4
wrengler4 Oct. 3 at 11:10 PM
$AGIO ..try “ know a thing or two” ALNY from $28 …and holding , still, REAL PROFESSIONALS YOU ARE HOLDING AGIOS, OR THE 3rd rate professionals Array , a Pfizer buy out Celgene ..another buy out, Mark Ales ( he got Jackie Fouse’s job at Celgene , lol…but you stick with her. SRPT back in 2017 @$28..to 100 in 8 months Sold this pos , Agios, back when it was $66 , jan 2018, knew they were losers , made more than the 50k your looking for , lol Knew then , Schenkien was a liar . You brag of this loser stock up 15 bucks in 10 months Go back to school , get a Wall Street education on “ who’s who “ ..Goff isn’t on that list ! Read my proof and weep , now or in 90 days , lol So many here assume, and set themselves up for humiliation, like Zelenskyy did to Trump on national TV, that was supposed to humiliate Zelenskyy, lol Ya know, like I just did to you, are you with the low iq of Trump, lol ! @CharlieeMungerTWITS
1 · Reply
wrengler4
wrengler4 Oct. 3 at 9:09 PM
$AGIO can’t fix stupid
0 · Reply
wrengler4
wrengler4 Oct. 3 at 9:07 PM
$AGIO BIG FCUKIN DEAL ..try YOY , hahahaha 30% RED Try 5 YEAR frame ..NEGATIVE 40% …hahaha Total losers hold this CEO says so, he sells options , every chance he gets !
1 · Reply
highnihilism
highnihilism Oct. 3 at 7:50 PM
$LPTH Lightpath Technologies Trades: 306 | Total $: 284.3 K | 1.50 × 90-Day Avg $: 189.7 K | Call $: 259.9 K | Put $: 24.5 K | Single-Leg: 97% | Multi-Leg: 3% $NLR Vaneck Uranium + Nuclear Energy ETF Trades: 157 | Total $: 292.9 K | 2.36 × 90-Day Avg $: 124.1 K | Call $: 257.3 K | Put $: 35.6 K | Single-Leg: 78% | Multi-Leg: 22% $CGC Canopy Growth Trades: 1,476 | Total $: 405.3 K | 1.13 × 90-Day Avg $: 358.7 K | Call $: 256.8 K | Put $: 148.5 K | Single-Leg: 87% | Multi-Leg: 13% $AGIO Agios Pharmaceuticals Trades: 47 | Total $: 494.3 K | 1.11 × 90-Day Avg $: 444.8 K | Call $: 256.6 K | Put $: 237.7 K | Single-Leg: 28% | Multi-Leg: 72%
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 3 at 7:50 PM
$KURA $ALDX $CORT $AGIO all bio with catalysts impending winners
0 · Reply
highnihilism
highnihilism Oct. 3 at 7:43 PM
$FTK Flotek Industries Trades: 94 | Total $: 273.5 K | 8.26 × 90-Day Avg $: 33.1 K | Call $: 257.6 K | Put $: 15.9 K | Single-Leg: 90% | Multi-Leg: 10% $NLR Vaneck Uranium + Nuclear Energy ETF Trades: 157 | Total $: 292.9 K | 2.36 × 90-Day Avg $: 124.1 K | Call $: 257.3 K | Put $: 35.6 K | Single-Leg: 78% | Multi-Leg: 22% $PBR Petrobras Brasileiro Trades: 978 | Total $: 1.12 M | 0.56 × 90-Day Avg $: 1.98 M | Call $: 257.2 K | Put $: 863.4 K | Single-Leg: 93% | Multi-Leg: 6% $AGIO Agios Pharmaceuticals Trades: 47 | Total $: 494.3 K | 1.11 × 90-Day Avg $: 444.8 K | Call $: 256.6 K | Put $: 237.7 K | Single-Leg: 28% | Multi-Leg: 72%
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 3 at 2:07 PM
$AGIO
0 · Reply
Jadek6
Jadek6 Oct. 3 at 10:29 AM
$AGIO ahh you have it backwards !! Only thing done here is OFF LOADING by executives Milanova Jones Goof Ball Goff And Bouse House Fouse They know they are that incompetent. GET THE FCUK OUT , is the office chatter !!! Soon …we will see Liar Schenkien, selling shares , he is over due to sell MORE !! @CharlieeMungerTWITS Schenkien , the lab rat, made wealthy , not by being a Dr., or here as a pathetic CEO, but by John Maraganore selling Millenial pharma , with his stock there, where he was a mere laboratory , lol, employee . Can a company ever muster up such losers.? They did here
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 2 at 11:49 PM
$AGIO whose loading ?!!!!!
0 · Reply
Latest News on AGIO
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Sep 18, 2025, 5:49 AM EDT - 16 days ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Sep 15, 2025, 12:20 PM EDT - 19 days ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Sep 8, 2025, 10:32 AM EDT - 26 days ago

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

Sep 4, 2025, 12:46 PM EDT - 4 weeks ago

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Sep 4, 2025, 10:49 AM EDT - 4 weeks ago

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Sep 4, 2025, 7:00 AM EDT - 4 weeks ago

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Aug 4, 2025, 4:01 PM EDT - 2 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:02 PM EDT - 2 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 6:30 AM EDT - 2 months ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 14, 2025, 7:00 AM EDT - 2 months ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jul 8, 2025, 7:00 AM EDT - 3 months ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Jun 9, 2025, 8:40 AM EDT - 4 months ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 28, 2025, 7:00 AM EDT - 4 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 14, 2025, 10:00 AM EDT - 5 months ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 9, 2025, 7:00 AM EDT - 5 months ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 2, 2025, 7:00 AM EDT - 5 months ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 12:06 PM EDT - 5 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 6:30 AM EDT - 5 months ago

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Apr 17, 2025, 7:00 AM EDT - 6 months ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Mar 5, 2025, 5:52 PM EST - 7 months ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Present at Upcoming Investor Conferences

Mar 4, 2025, 7:00 AM EST - 7 months ago

Agios to Present at Upcoming Investor Conferences

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Feb 20, 2025, 7:00 AM EST - 8 months ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 1:32 PM EST - 8 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 13, 2025, 6:31 AM EST - 8 months ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Feb 13, 2025, 6:30 AM EST - 8 months ago

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Feb 6, 2025, 7:00 AM EST - 8 months ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

Jan 8, 2025, 8:00 AM EST - 9 months ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BIIB

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Jan 3, 2025, 7:00 AM EST - 9 months ago

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

Dec 18, 2024, 7:00 AM EST - 10 months ago

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Dec 8, 2024, 12:40 PM EST - 10 months ago

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Nov 5, 2024, 9:05 AM EST - 11 months ago

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 2:16 PM EDT - 1 year ago

Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Aug 27, 2024, 10:18 AM EDT - 1 year ago

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Aug 6, 2024, 5:50 PM EDT - 1 year ago

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

Aug 1, 2024, 1:42 PM EDT - 1 year ago

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 12:11 PM EDT - 1 year ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

Aug 1, 2024, 6:31 AM EDT - 1 year ago

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Jul 18, 2024, 7:00 AM EDT - 1 year ago

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 12, 2024, 7:41 AM EDT - 1 year ago

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

Jun 3, 2024, 6:42 AM EDT - 1 year ago

Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Jun 3, 2024, 6:30 AM EDT - 1 year ago

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 30, 2024, 4:05 PM EDT - 1 year ago

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

May 14, 2024, 10:00 AM EDT - 1 year ago

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

SweepCastApp
SweepCastApp Oct. 4 at 12:30 AM
$AGIO: Unusual Options Activity Alerted CALL flow observed 50x contracts at Strike price of $35 Exp on 10/17/2025 with Premium of $31K and showing NEUTRAL Sentiment
0 · Reply
wrengler4
wrengler4 Oct. 3 at 11:10 PM
$AGIO ..try “ know a thing or two” ALNY from $28 …and holding , still, REAL PROFESSIONALS YOU ARE HOLDING AGIOS, OR THE 3rd rate professionals Array , a Pfizer buy out Celgene ..another buy out, Mark Ales ( he got Jackie Fouse’s job at Celgene , lol…but you stick with her. SRPT back in 2017 @$28..to 100 in 8 months Sold this pos , Agios, back when it was $66 , jan 2018, knew they were losers , made more than the 50k your looking for , lol Knew then , Schenkien was a liar . You brag of this loser stock up 15 bucks in 10 months Go back to school , get a Wall Street education on “ who’s who “ ..Goff isn’t on that list ! Read my proof and weep , now or in 90 days , lol So many here assume, and set themselves up for humiliation, like Zelenskyy did to Trump on national TV, that was supposed to humiliate Zelenskyy, lol Ya know, like I just did to you, are you with the low iq of Trump, lol ! @CharlieeMungerTWITS
1 · Reply
wrengler4
wrengler4 Oct. 3 at 9:09 PM
$AGIO can’t fix stupid
0 · Reply
wrengler4
wrengler4 Oct. 3 at 9:07 PM
$AGIO BIG FCUKIN DEAL ..try YOY , hahahaha 30% RED Try 5 YEAR frame ..NEGATIVE 40% …hahaha Total losers hold this CEO says so, he sells options , every chance he gets !
1 · Reply
highnihilism
highnihilism Oct. 3 at 7:50 PM
$LPTH Lightpath Technologies Trades: 306 | Total $: 284.3 K | 1.50 × 90-Day Avg $: 189.7 K | Call $: 259.9 K | Put $: 24.5 K | Single-Leg: 97% | Multi-Leg: 3% $NLR Vaneck Uranium + Nuclear Energy ETF Trades: 157 | Total $: 292.9 K | 2.36 × 90-Day Avg $: 124.1 K | Call $: 257.3 K | Put $: 35.6 K | Single-Leg: 78% | Multi-Leg: 22% $CGC Canopy Growth Trades: 1,476 | Total $: 405.3 K | 1.13 × 90-Day Avg $: 358.7 K | Call $: 256.8 K | Put $: 148.5 K | Single-Leg: 87% | Multi-Leg: 13% $AGIO Agios Pharmaceuticals Trades: 47 | Total $: 494.3 K | 1.11 × 90-Day Avg $: 444.8 K | Call $: 256.6 K | Put $: 237.7 K | Single-Leg: 28% | Multi-Leg: 72%
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 3 at 7:50 PM
$KURA $ALDX $CORT $AGIO all bio with catalysts impending winners
0 · Reply
highnihilism
highnihilism Oct. 3 at 7:43 PM
$FTK Flotek Industries Trades: 94 | Total $: 273.5 K | 8.26 × 90-Day Avg $: 33.1 K | Call $: 257.6 K | Put $: 15.9 K | Single-Leg: 90% | Multi-Leg: 10% $NLR Vaneck Uranium + Nuclear Energy ETF Trades: 157 | Total $: 292.9 K | 2.36 × 90-Day Avg $: 124.1 K | Call $: 257.3 K | Put $: 35.6 K | Single-Leg: 78% | Multi-Leg: 22% $PBR Petrobras Brasileiro Trades: 978 | Total $: 1.12 M | 0.56 × 90-Day Avg $: 1.98 M | Call $: 257.2 K | Put $: 863.4 K | Single-Leg: 93% | Multi-Leg: 6% $AGIO Agios Pharmaceuticals Trades: 47 | Total $: 494.3 K | 1.11 × 90-Day Avg $: 444.8 K | Call $: 256.6 K | Put $: 237.7 K | Single-Leg: 28% | Multi-Leg: 72%
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 3 at 2:07 PM
$AGIO
0 · Reply
Jadek6
Jadek6 Oct. 3 at 10:29 AM
$AGIO ahh you have it backwards !! Only thing done here is OFF LOADING by executives Milanova Jones Goof Ball Goff And Bouse House Fouse They know they are that incompetent. GET THE FCUK OUT , is the office chatter !!! Soon …we will see Liar Schenkien, selling shares , he is over due to sell MORE !! @CharlieeMungerTWITS Schenkien , the lab rat, made wealthy , not by being a Dr., or here as a pathetic CEO, but by John Maraganore selling Millenial pharma , with his stock there, where he was a mere laboratory , lol, employee . Can a company ever muster up such losers.? They did here
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 2 at 11:49 PM
$AGIO whose loading ?!!!!!
0 · Reply
Jadek6
Jadek6 Oct. 2 at 11:09 PM
$AGIO someone drinks too much 10 months later, these misfits haven’t changed anything … They keep stumbling, but they love the 1.4B they have to piss away .
0 · Reply
ImPoorAndHungry
ImPoorAndHungry Oct. 1 at 9:07 PM
$AGIO fck Oppenheimer. This shit going to $45. I’m back in
0 · Reply
ImPoorAndHungry
ImPoorAndHungry Oct. 1 at 5:31 PM
$AGIO why’d I sell 😢 this is about to pop 😞
0 · Reply
Quantumup
Quantumup Oct. 1 at 2:41 PM
Oppenheimer reiterated $FULC at an Outperform rating and a $15 price target: $XBI $AGIO $NVS $VRTX Oppenheimer said: We've been getting questions on how updated pociredir data later this year will impact FULC shares. For us, the readout is more "icing on the cake," rather than major binary because we already thought pociredir looked like a drug at the lower 12 mg dose. Absent any idiosyncratic toxicity or material weakening of efficacy, shares should continue to grind higher. However, given Fulcrum's recent run (shares are up 80% YTD vs. the XBI ahead 9%), it's fair to assume that the buyside's internal bar may be higher than our own. Based on our field work, that bar appears to be a 10% or higher HbF improvement. We believe that's achievable based on prior healthy volunteer data.
0 · Reply
wrengler4
wrengler4 Oct. 1 at 12:12 AM
$AGIO This stock found another Dreamer Did they miss you on the raid at the border ? And you chose this pos over AAPL Hahahaha There is no TIM COOK HERE … But there is Charlie Javice stereotypes galore here
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 30 at 11:49 PM
$AGIO LETS GO BABY !!!! CATALYST INBOUND!
0 · Reply
highnihilism
highnihilism Sep. 30 at 6:27 AM
$PCG: 1.3K trades, $809K vs $3.1M avg (0.26x). Bullish skew: $653K calls/$156K puts. 73% single-leg. $PCT: 785 trades, $880K vs $1.9M avg (0.46x). Bullish skew: $648K calls/$233K puts. 89% single-leg. $AGIO: 398 trades, $660K vs $437K avg (1.51x). Bullish skew: $645K calls/$14K puts. 100% single-leg. $CFLT: 714 trades, $691K vs $1.8M avg (0.38x). Bullish skew: $644K calls/$47K puts. 94% single-leg.
0 · Reply
Dkll303
Dkll303 Sep. 29 at 11:31 PM
$AGIO head over to the pink sheets, this arena is out of your purchase power !
1 · Reply
ImPoorAndHungry
ImPoorAndHungry Sep. 29 at 8:20 PM
$AGIO damn. Just realized I’m up $550 with today’s gains. Peace bitties ✌️
0 · Reply
Dkll303
Dkll303 Sep. 29 at 11:13 AM
$AGIO $CRS $DRD $GPUS $QMMM Not here !!! But nice cartoon
0 · Reply
Dkll303
Dkll303 Sep. 29 at 11:12 AM
$AGIO is this news ??? Hahaha…the senior mgmt misfits have that all factored in !!! Incompetence abounds here
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 6:57 AM
$AGIO: Unusual Options Activity Alerted CALL flow observed 50x contracts at Strike price of $40 Exp on 02/20/2026 with Premium of $52K and showing BEARISH Sentiment
0 · Reply